Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02697188 · ClinicalTrials.gov registry record · Phase 2
Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men
A Phase 2 study, sponsored by Clarus Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02697188 is a Phase 2 study that has completed, run by Clarus Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT02697188, a Phase 2 study, has completed, sponsored by Clarus Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Determine the serum pharmacokinetic profile for two oral formulations of T-esters (one TE and one TU) administered once -(QD) and twice-daily (BID) to hypogonadal men.
Interventions
- DRUG Testosterone enanthate
- DRUG Testosterone undecanoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02697188
The ClinicalTrials.gov registry entry for NCT02697188 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clarus Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Testosterone enanthate is the first listed.
NCT02697188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02697188 about?
NCT02697188 is a clinical study titled "Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men". Determine the serum pharmacokinetic profile for two oral formulations of T-esters (one TE and one TU) administered once -(QD) and twice-daily (BID) to hypogonadal men.
What is the current status of trial NCT02697188?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2007-11. Estimated completion is 2008-04.
What interventions are being tested in trial NCT02697188?
The interventions under investigation include: Testosterone enanthate (DRUG), Testosterone undecanoate (DRUG).
Who is sponsoring clinical trial NCT02697188?
This trial is sponsored by Clarus Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.